Abiopharma

🔍 Rose Geoffrey Beran (Executive)

Company: Pulmonx Corp (LUNG)

Report Date: 2025-09-02

Detailed Transactions and Holdings:

• Sold 707 shares of Common Stock at $1.6 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 385,624.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,799 shares of Common Stock at $1.6 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 383,825.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,575 shares of Common Stock at $1.6 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 382,250.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 2,462 shares of Common Stock at $1.6 per share (Direct)
  Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 379,788.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units (the "RSUs") granted on March 1, 2022.
• F2: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2023.
• F3: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 1, 2024.
• F4: These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs granted on March 3, 2025.